drugset / Trial / NCT07104877
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors
NaSequentialOpen-labelTreatment
Summary
This study is an open-label, non-randomized trial design, including a dose escalation phase and a dose expansion phase, to evaluate the safety, tolerability and preliminary anti-tumor activity of SYS6010 in combination with SYH2051 in patients with advanced gastrointestinal tumors.
Timeline
- Start
- 2024-04-18
- Primary completion
- 2024-11-01
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYH2051 | Unknown | 40 mg | Oral |
| Subject | SYH2051 | Unknown | 80 mg | Oral |
| Subject | SYS6010 | Monoclonal antibody | 3.2 mg/kg | Intravenous |
| Subject | SYS6010 | Monoclonal antibody | 4.8 mg/kg | Intravenous |